Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | BAZ2B | Q9UIF8 | 2/20 | 0.47 |
| ▸ | HTR1B | P28222 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8241723 | 1.00 | SIRT1 (1.00) | SIRT1MAPTBAZ2BHTR1BHSD17B10 | |
| SCHEMBL8241727 | 1.00 | SIRT1 (1.00) | SIRT1MAPTBAZ2BHTR1BHSD17B10 | |
| SCHEMBL1874857 | 0.88 | SIRT1 (0.79) | SIRT1MAPTBAZ2BHSD17B10ALDH1A1 | |
| SCHEMBL11680018 | 0.85 | SIRT1 (1.00) | SIRT1MAPTBAZ2BMAPK1 | |
| SCHEMBL8592516 | 0.81 | SIRT1 (0.68) | SIRT1 | |
| Hydrochloric Acid SCHEMBL8595142 | 0.80 | SIRT1 (0.67) | SIRT1 | |
| SCHEMBL16265980 | 0.79 | SIRT1 (0.65) | SIRT1HTR1BHTR1D | |
| SCHEMBL20615464 | 0.77 | SIRT1 (0.62) | SIRT1MAPTBAZ2BALDH1A1MAPK1 | |
| SCHEMBL11269215 | 0.77 | SIRT1 (0.62) | SIRT1MAPTBAZ2B | |
| Hydrochloric Acid SCHEMBL20601993 | 0.76 | SIRT1 (0.61) | SIRT1MAPTBAZ2BALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140030295-A1 | Use of Sirt1 Activators or Inhibitors to Modulate an Immune Response | THE J. DAVID GLADSTONE INSTITUTES (US) | 2014-01-30 | — | — | US | claimed |
| US-20100330114-A1 | Use of SIRT1 Activators or Inhibitors to Modulate an Immune Response | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-12-30 | — | — | US | claimed |
| WO-2009099643-A1 | USE OF SIRT1 ACTIVATORS OR INHIBITORS TO MODULATE AN IMMUNE RESPONSE | THE J. DAVID GLADSTONE INSTITUTES (US) | 2009-08-13 | — | — | WO | claimed |
| US-20160113903-A1 | SirT INHIBITORS THAT BIND TO NAD | ELIXIR PHARMACEUTICALS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| EP-1677794-B1 | METHODS OF TREATING DISORDER | ELIXIR PHARMACEUTICALS INC (US) | 2014-12-03 | — | — | EP | disclosed |
| US-20140163029-A1 | SirT INHIBITORS THAT BIND TO NAD | ELIXIR PHARMACEUTICALS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-8748464-B2 | Use of SIRT1 activators or inhibitors to modulate an immune response | THE J. DAVID GLADSTONE INSTITUTES (US) | 2014-06-10 | — | — | US | disclosed |
| US-20140030295-A1 | Use of Sirt1 Activators or Inhibitors to Modulate an Immune Response | THE J. DAVID GLADSTONE INSTITUTES (US) | 2014-01-30 | — | — | US | disclosed |
| US-20110104177-A1 | HISTONE DEACETYLASE INHIBITORS, COMBINATION THERAPIES AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-05-05 | — | — | US | disclosed |
| US-20100330114-A1 | Use of SIRT1 Activators or Inhibitors to Modulate an Immune Response | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-12-30 | — | — | US | disclosed |
| US-20100210692-A1 | METHODS OF TREATMENT USING SIRT MODULATORS AND COMPOSITIONS CONTAINING SIRT1 MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-08-19 | — | — | US | disclosed |
| US-20090306168-A1 | SirT Inhibitors That Bind to NAD | ELIXIR PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| WO-2009099643-A1 | USE OF SIRT1 ACTIVATORS OR INHIBITORS TO MODULATE AN IMMUNE RESPONSE | THE J. DAVID GLADSTONE INSTITUTES (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090022694-A1 | SIRT1 INHIBITION | ELIXIR PHARMACEUTICALS, INC. | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160113903-A1 | SirT INHIBITORS THAT BIND TO NAD | SIRT1, SIRT3, SIRT2 | SIRT1 1/4885MAPT 451/4885BAZ2B 250/4885 |
| US-20100330114-A1 | Use of SIRT1 Activators or Inhibitors to Modulate an Immune Response | SIRT1, SIRT2, NFATC1 | SIRT1 1/4885MAPT 2086/4885BAZ2B 600/4885 |
| US-20100210692-A1 | METHODS OF TREATMENT USING SIRT MODULATORS AND COMPOSITIONS CONTAINING SIRT1 MODULATORS | SIRT1, SIRT2, SIRT3 | SIRT1 1/4885MAPT 2723/4885BAZ2B 213/4885 |
| US-20140030295-A1 | Use of Sirt1 Activators or Inhibitors to Modulate an Immune Response | SIRT1, SIRT2, NFATC1 | SIRT1 1/4885MAPT 2086/4885BAZ2B 600/4885 |
| US-20090022694-A1 | SIRT1 INHIBITION | SIRT1, SIRT2, SIRT3 | SIRT1 1/4885MAPT 2639/4885BAZ2B 306/4885 |
| US-20110104177-A1 | HISTONE DEACETYLASE INHIBITORS, COMBINATION THERAPIES AND METHODS OF USE | HDAC1, HDAC5, HDAC4 | SIRT1 12/4885MAPT 3378/4885BAZ2B 27/4885 |
| US-20140163029-A1 | SirT INHIBITORS THAT BIND TO NAD | SIRT1, SIRT3, SIRT2 | SIRT1 1/4885MAPT 451/4885BAZ2B 250/4885 |
| US-20090306168-A1 | SirT Inhibitors That Bind to NAD | SIRT1, SIRT3, SIRT2 | SIRT1 1/4885MAPT 451/4885BAZ2B 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.